Catalent can achieve long-term growth and margin targets, says Piper Jaffray

Piper Jaffray analyst Sean Wieland kept his Overweight rating and $49 price target on Catalent after its Q4 earnings beat, saying the company’s Biologics segment carried the “bulk of growth” while Softgel “waned”. The analyst states that he remains confident in the company’s long-term growth and margin targets in spite of the near term headwinds.
https://bit.ly/2LyT88J